Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03238703
Other study ID # 9764
Secondary ID NCI-2017-0072497
Status Withdrawn
Phase Phase 4
First received
Last updated
Start date September 1, 2018
Est. completion date March 14, 2025

Study information

Verified date December 2018
Source Fred Hutchinson Cancer Research Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot clinical trial studies how well endocrine therapy works in treating patients with HER2 negative, low risk breast cancer. Estrogen can cause the growth of breast cancer cells. Endocrine therapies such as aromatase inhibitors and selective estrogen receptor modulators may lessen the amount of estrogen made by the body.


Description:

PRIMARY OBJECTIVES:

I. To estimate the conversion rate from a standard low-toxicity approach to guideline-directed therapy which includes surgery +/- radiation therapy as a result of progression of disease or patient/provider choice.

II. To examine factors that might differ between those who convert from the low-toxicity approach to the guideline-directed therapy and those do not convert.

SECONDARY OBJECTIVES:

I. To measure the safety and clinical effectiveness of systemic endocrine therapy used in a prolonged neoadjuvant fashion.

II. To evaluate the impact of risk-stratified care in Quality-Adjusted Life Years (QALY) and QALY gains.

III. To estimate the cost savings of indefinitely delaying surgery and radiation in favor of systemic endocrine therapy alone.

OUTLINE:

Patients receive exemestane orally (PO) once daily (QD), anastrozole PO QD, letrozole PO QD, tamoxifen citrate PO QD, or toremifene citrate PO QD at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 14, 2025
Est. primary completion date March 14, 2023
Accepts healthy volunteers No
Gender Female
Age group 60 Years and older
Eligibility Inclusion Criteria:

- Able to provide written informed consent

- A diagnosis of invasive breast cancer, with or without an in situ component, that is:

- Originally identified by screening mammography

- Characterized by standard diagnostic mammography +/- breast ultrasound

- Clinically node negative

- Confirmed by breast magnetic resonance imaging (MRI) in a facility that maintains active American College of Radiology (ACR) accreditation to be of low clinical stage (=< 2 cm, node negative, unifocal invasive)

- Estrogen receptor (ER) and progesterone receptor (PR) Allred scored, each > 5/8

- Her2 negative using American Society of Clinical Oncology (ASCO)-College of American Pathologists (CAP) guidelines

- ki-67 proliferation scored, < 20%

- Clinical Nottingham grade 1 or 2

- Scored on the MammaPrint 70-gene breast cancer recurrence assay as low risk

- Prior to the discovery of the breast cancer, clinically post-menopausal as defined as: i) one or more years from last menses; or ii) history of oophorectomy; or iii) follicle stimulating hormone (FSH) test result in the post-menopause reference range

- Willing to accept oral endocrine therapy with a third generation aromatase inhibitor (AI) or selective estrogen receptor modifier (SERM)

- Willing to undergo routine surveillance with breast ultrasound and/or mammography

Exclusion Criteria:

- Known contraindication to aromatase inhibitor or SERM therapy

- Pregnant at time of or within prior year of diagnosis

- Clinically detected or palpable disease prior to biopsy in either breast or ipsilateral axilla

- Prior history of invasive breast cancer or ductal breast carcinoma in situ (DCIS)

- Prior use of aromatase inhibitor therapy apart from assisted reproduction

- Prior use of SERM

- Unmanaged/uncontrolled mental health disorder

- Life expectancy < 6 months (m) for any cause

- Biopsy confirmed multifocal, multicentric, or contralateral disease that is invasive or non-invasive

- DCIS with focal invasion

Study Design


Intervention

Drug:
Anastrozole
Given PO
Exemestane
Given PO
Other:
Laboratory Biomarker Analysis
Correlative studies
Drug:
Letrozole
Given PO
Other:
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Drug:
Tamoxifen Citrate
Given PO
Toremifene Citrate
Given PO

Locations

Country Name City State
United States Fred Hutch/University of Washington Cancer Consortium Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Conversion from oral endocrine therapy for any reason to guideline-directed therapy Includes clinical or radiographic progression, patient preference, endocrine therapy intolerance or toxicity, or death from any cause. Descriptive statistics will be summarized among all patients and patients within each of the two groups (stay with oral therapy vs conversion due to any causes). Up to 5 years
Secondary Advanced imaging (if performed on any subset of patients) Will be compared to a concurrent group of patients managed in the conventional manner with upfront surgery +/- radiation therapy followed by systemic endocrine therapy. Descriptive statistics will be summarized among all patients and patients within each of the two groups (stay with oral therapy vs conversion due to any causes). Up to 5 years
Secondary Cost-effectiveness and patient-centeredness outcomes defined as financial toxicity and solubility, quality of life (physical, mental, emotional changes) on endocrine therapy, and, access to support services Comparisons will be made to historical benchmarks for similar patients managed in a conventional locoregional manner for early-stage breast cancer. Descriptive statistics will be summarized among all patients and patients within each of the two groups (stay with oral therapy vs conversion due to any causes). Up to 5 years
Secondary Effect of age Will be compared to a concurrent group of patients managed in the conventional manner with upfront surgery +/- radiation therapy followed by systemic endocrine therapy. Descriptive statistics will be summarized among all patients and patients within each of the two groups (stay with oral therapy vs conversion due to any causes). Up to 5 years
Secondary Effect of comorbidity severity interaction Will be compared to a concurrent group of patients managed in the conventional manner with upfront surgery +/- radiation therapy followed by systemic endocrine therapy. Descriptive statistics will be summarized among all patients and patients within each of the two groups (stay with oral therapy vs conversion due to any causes). Up to 5 years
Secondary Effect of type of endocrine therapy type (selective estrogen receptor modifier versus aromatase inhibitor) Will be compared to a concurrent group of patients managed in the conventional manner with upfront surgery +/- radiation therapy followed by systemic endocrine therapy. Descriptive statistics will be summarized among all patients and patients within each of the two groups (stay with oral therapy vs conversion due to any causes). Up to 5 years
Secondary Effects emanating from tertiary care Will be compared to a concurrent group of patients managed in the conventional manner with upfront surgery +/- radiation therapy followed by systemic endocrine therapy. Descriptive statistics will be summarized among all patients and patients within each of the two groups (stay with oral therapy vs conversion due to any causes). Up to 5 years
Secondary Progression of disease while on primary endocrine therapy, as measured objectively by routine diagnostic breast imaging (mammography and/or ultrasound) Descriptive statistics will be summarized among all patients and patients within each of the two groups (stay with oral therapy vs conversion due to any causes). Up to 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting NCT04521764 - A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer Phase 1
Completed NCT02689427 - Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer Phase 2
Terminated NCT00148720 - Capecitabine in Women With Operable Breast Cancer Phase 2
Recruiting NCT05464810 - Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer Early Phase 1
Suspended NCT03737695 - Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer
Recruiting NCT05406232 - Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
Completed NCT03679559 - Exercise in Improving Health and Quality of Life in Breast Cancer Survivors N/A
Active, not recruiting NCT02876107 - Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer Phase 2
Active, not recruiting NCT02445391 - Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy Phase 3
Completed NCT01964924 - Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Phase 2
Recruiting NCT02276443 - Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative N/A
Recruiting NCT05545150 - Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study Phase 2
Active, not recruiting NCT03359954 - Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer Phase 2
Active, not recruiting NCT01245712 - Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer Phase 2
Active, not recruiting NCT05012176 - An Episodic Future Thinking Intervention to Promote Weight Loss in Breast Cancer Survivors N/A
Active, not recruiting NCT01334021 - Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer Phase 2
Completed NCT05071677 - Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer
Recruiting NCT04169542 - Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
Completed NCT01753908 - Broccoli Sprout Extract in Treating Patients With Breast Cancer Early Phase 1